|3.||Wounds and Injuries (Trauma)
|5.||Critical Illness (Critically Ill)
|1.||Chastre, Jean: 27 articles (01/2015 - 04/2002)|
|2.||Kollef, Marin H: 24 articles (06/2015 - 11/2002)|
|3.||Rello, Jordi: 17 articles (08/2015 - 06/2003)|
|4.||Combes, Alain: 17 articles (01/2014 - 04/2003)|
|5.||Trouillet, Jean-Louis: 16 articles (01/2014 - 04/2003)|
|6.||Luyt, Charles-Edouard: 16 articles (01/2014 - 10/2004)|
|7.||Rosenthal, Victor D: 16 articles (04/2013 - 04/2006)|
|8.||Fabian, Timothy C: 15 articles (01/2016 - 06/2002)|
|9.||Croce, Martin A: 14 articles (01/2016 - 06/2002)|
|10.||Klompas, Michael: 12 articles (07/2015 - 12/2007)|
|1.||Colistin (Coly-Mycin)FDA Link
12/01/2012 - "In this study we aimed to assess the safety and efficacy of high-dose IV colistin (COL) and aerosolized COL for the treatment of Acinetobacter baumannii ventilator-associated pneumonia (VAP). "
12/01/2012 - "Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii."
08/01/2007 - "Colistin-susceptible ventilator-associated pneumonia episodes can be effectively treated using colistin without significant renal dysfunction. "
03/01/2015 - "Based on the present results and awaiting further evidence from randomized trials, aerosolized colistin is associated with improved outcome in the treatment of ventilator-associated pneumonia although the level of evidence was low."
12/01/2012 - "The aim of the study was to assess efficacy of nebulized colistin for treating ventilator-associated pneumonia (VAP) caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. "
|2.||Anti-Bacterial Agents (Antibiotics)IBA
01/01/2015 - "Nebulized antibiotics are a promising new treatment option for ventilator-associated pneumonia. "
01/01/2013 - "In patients with ventilator-associated pneumonia (VAP), administration of an appropriate empirical antimicrobial treatment is associated with improved outcomes, leading to the prescription of broad-spectrum antibiotics, including a drug active against methicillin resistant Staphylococcus aureus (MRSA). "
07/01/2012 - "Each group included one case of ventilator-associated pneumonia that was later cured with antibiotics. "
02/01/2006 - "Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia."
01/01/2015 - "The Medline, Scopus, EMBASE, Biological Abstracts, CAB Abstracts, Food Science and Technology Abstracts, CENTRAL, Scielo and Lilacs databases were searched to identify randomized controlled trials or matched observational studies that compared nebulized antibiotics with or without intravenous antibiotics to intravenous antibiotics alone for ventilator-associated pneumonia treatment. "
01/01/2015 - "Furthermore, through the review of studies evaluating the efficacy of chlorhexidine, we found that, despite the presence of mixed results, that chlorhexidine may be a particularly effective means of lowering the risk for hospital-acquired and ventilator-associated pneumonia. "
09/01/2012 - "To study the efficacy of oral mucosal decontamination with chlorhexidine gel for the prevention of ventilator-associated pneumonia in children between 3 months and 15 yrs. "
05/01/2013 - "This article evaluates the evidence for and efficacy of the use of mechanical hygiene and chlorhexidine in the prevention of ventilator-associated pneumonia (VAP). "
02/01/2007 - "To assess the efficacy of topical chlorhexidine for prevention of ventilator-associated pneumonia (VAP) in a meta-analysis. "
12/01/2015 - "Reduced occurrence of ventilator-associated pneumonia after cardiac surgery using preoperative 0.2% chlorhexidine oral rinse: results from a single-centre single-blinded randomized trial."
|4.||meropenem (Merrem)FDA LinkGeneric
02/01/2006 - "To evaluate the clinical efficacy of continuous versus intermittent infusion of meropenem for the treatment of ventilator-associated pneumonia (VAP) due to gram-negative bacilli. "
02/01/2001 - "Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia."
01/01/2001 - "[Efficacy of monotherapy by meropenem in ventilator-associated pneumonia]."
04/01/2011 - "Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia."
03/01/2009 - "Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii."
11/01/2013 - "Current guidelines for the empiric treatment of ventilator-associated pneumonia (VAP) recommend that vancomycin is dosed 15 mg/kg and administered twice daily for a target trough level of 15 to 20 μg/mL. This study compared conventional intermittent vancomycin infusion (IVI) with continuous vancomycin infusion (CVI). "
06/01/2009 - "The objective of this surveillance study was to determine vancomycin MIC distributions for MRSA isolates collected from the respiratory tract of patients with ventilator-associated pneumonia (VAP) at a large community hospital in Hartford, Connecticut. "
06/01/2009 - "Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospital."
01/01/2008 - "Methicillin-resistant (methicillin-resistant) Staphylococcus aureus causes unacceptably high mortality from ventilator-associated pneumonia, even when appropriate early therapy with vancomycin is administered at a dosage of 15 mg/kg every 12 hours. "
01/01/2008 - "Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?"
|6.||Ceftazidime (Fortum)FDA LinkGeneric
11/01/2007 - "The objective of this study was to compare the clinical efficacy of ceftazidime administered by continuous infusion and by intermittent infusion in the treatment of ventilator-associated pneumonia (VAP) caused by gram-negative bacteria. "
08/01/2002 - "To evaluate the safety and efficacy of aerosolized ceftazidime for prevention of ventilator-associated pneumonia (VAP) and to evaluate the effects of the drug on the proinflammatory response. "
04/01/2015 - "This study of ceftazidime concentrations in the epithelial lining fluid indicates that continuous infusion presents advantages in terms of pharmacodynamics and predictable efficacy in patients presenting ventilator-associated pneumonia. "
07/01/2015 - "Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia."
04/01/2015 - "Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia."
|7.||linezolid (Zyvox)FDA Link
01/01/2004 - "Despite its higher cost, linezolid was cost-effective for treatment of ventilator-associated pneumonia. "
05/01/2012 - "In this study, the potential of linezolid to protect patients with ventilator-associated pneumonia (VAP) from developing CDI was assessed. "
01/01/2004 - "Model estimates were derived from prospective trials of linezolid for ventilator-associated pneumonia and from other studies describing the costs and outcomes for ventilator-associated pneumonia. "
03/01/2009 - "Affect of linezolid in ventilator-associated pneumonia caused by MRSA."
05/01/2012 - "This study aimed to determine the steady-state serum and alveolar concentrations of linezolid administered by continuous infusion to critically ill patients with ventilator-associated pneumonia (VAP). "
05/01/2008 - "A target piperacillin serum concentration of at least 35-40 mg/L is probably required to provide alveolar concentrations exceeding the susceptibility breakpoint for gram-negative bacteria (16 mg/L) during ventilator-associated pneumonia. "
12/01/2006 - "Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia."
04/15/2002 - "We sought to determine the epidemiological characteristics of patients in an intensive care unit (ICU) who developed ventilator-associated pneumonia (VAP) caused by piperacillin-resistant Pseudomonas aeruginosa (PRPA; n=34) or piperacillin-susceptible P. "
04/15/2002 - "Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms."
03/01/2008 - "The aim of this study is to describe the effect of PE on the serum and subcutaneous tissue pharmacokinetics of piperacillin administered as a continuous infusion in a critically ill 17-year-old patient with Guillain-Barré syndrome and ventilator-associated pneumonia on Days 1 and 4 of antibiotic therapy. "
09/01/2014 - "Ceftolozane/tazobactam is under clinical development for treatment of complicated intra-abdominal infections (IAI), complicated urinary tract infections (UTI) and ventilator-associated pneumonia. "
01/01/2013 - "A Phase III, multicenter, prospective, randomized, open-label study has been initiated to evaluate the safety and efficacy of ceftolozane/tazobactam versus piperacillin/tazobactam for the treatment of ventilator-associated pneumonia. "
07/01/2012 - "Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia."
02/01/2012 - "Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs."
05/01/2009 - "Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion."
|10.||Sucralfate (Carafate)FDA LinkGeneric
05/15/2004 - "Sedation, sucralfate, and antibiotic use are potential means for protection against early-onset ventilator-associated pneumonia."
01/01/2010 - "Prophylaxis with sucralfate decreased the incidence of gastric colonization (OR = 2.03, 95% CI: 1.29 to 3.19) and ventilator-associated pneumonia (OR = 1.32, 95% CI: 1.07 to 1.64). "
01/01/2014 - "To evaluate the effect of sucralfate and acid-suppressive drugs on preventing ventilator-associated pneumonia (VAP) in mechanically ventilated patients. "
01/01/2014 - "[Effects of sucralfate and acid-suppressive drugs on preventing ventilator- associated pneumonia of mechanically ventilated patients: a meta-analysis]."
05/01/2004 - "Semirecumbent positioning in all eligible patients, sucralfate rather than H2 antagonists in patients at low to moderate risk of gastrointestinal bleeding, and, in selected patients, aspiration of subglottic secretions and oscillating beds are the measures proposed to prevent the development of ventilator-associated pneumonia. "
|1.||Mechanical Ventilators (Ventilator)
10/01/2011 - "Compared to the preintervention period, there was a significant reduction in ventilator-associated pneumonia in the postintervention period (32 cases per 1,000 ventilator days to 12 cases per 1,000 ventilator days; p<.001). "
03/01/2009 - "Efficacy of an expanded ventilator bundle for the reduction of ventilator-associated pneumonia in the medical intensive care unit."
04/01/2008 - "To determine if the knowledge and awareness of "ventilator bundle" helped in the prevention of ventilator associated pneumonia and other outcome variables in the patients admitted to our AICU. "
12/01/2004 - "To analyze the efficacy of periodically changing ventilator circuits for decreasing the rate of ventilator-associated pneumonia when a heat and moisture exchanger (HME) is used for humidification. "
01/01/2015 - "The objective of the study was to confirm the effect of subglottic secretion suctioning on ventilator-associated pneumonia prevalence and to assess its concomitant impact on ventilator-associated conditions and antibiotic use. "
|2.||Artificial Respiration (Mechanical Ventilation)
10/01/2012 - "The results of meta analysis showed that CTSS was associated with a significant reduction in the duration of mechanical ventilation (WMD = -0.73, 95%CI -1.07 - -0.40, P < 0.0001), but the incidence of ventilator associated pneumonia and microbial colonization, mortality and length of ICU stay exhibited no difference between the two groups (P > 0.05). "
01/01/2005 - "Subglottic secretion drainage appears effective in preventing early-onset ventilator-associated pneumonia among patients expected to require >72 hours of mechanical ventilation."
02/01/2008 - "To review the effectiveness of prone position as compared with supine position, with respect to mortality, improvement in oxygenation, number of days on mechanical ventilation, and ventilator-associated pneumonia. "
03/01/2012 - "The present study aimed to review the effects of an oral care practice on the incidence of ventilator-associated pneumonia in patients on mechanical ventilation admitted in ICUs. "
03/01/2010 - "Meta-analysis of randomized controlled trials comparing probiotics and control in patients undergoing mechanical ventilation and reporting on incidence of ventilator-associated pneumonia. "
|3.||Intensive Care (Surgical Intensive Care)
04/01/2003 - "This review aims to identify which method of humidification is most effective in Intensive Care patients intubated and ventilated for longer than 48hours with regard to the prevention of tracheal tube occlusion and the incidence of ventilator associated pneumonia (VAP). "
01/01/2012 - "A program for sustained improvement in preventing ventilator associated pneumonia in an intensive care setting."
06/01/2015 - "Efficacy of ventilator-associated pneumonia care bundle for prevention of ventilator-associated pneumonia in the surgical intensive care units of a medical center."
01/01/2013 - "The aim of this study was to evaluate antimicrobial usage, incidence, etiology, and antimicrobial resistance trends for prominent nosocomial pathogens causing ventilator-associated pneumonia in a clinical-surgical intensive care unit (ICU). "
09/01/2012 - "[Bacteriological study of bronchoalveolar lavage in the antibiotic management of suspected ventilator-associated pneumonia of patients in surgical intensive care units]."
10/01/2014 - "Catheter-related BSIs (CR-BSIs) and ventilator-associated pneumonia (VAP) were the most common causes (29.4 and 20.9%, respectively). "
09/01/2013 - "Mechanical cleaning with sterile urethral catheters reduced bacterial colonization, prevented formation of endotracheal tube biofilm, and reduced the occurrence of ventilator-associated pneumonia."
12/01/2009 - "[A comparison of the blind double-lumen plugged telescoping catheter with protected specimen brush for the diagnosis of ventilator-associated pneumonia.]."
02/01/2006 - "Ventilator-associated pneumonia was confirmed by a bacterial culture of a blind protected telescoping catheter with at least 10 colony-forming units/ml of at least one pathogen. "
11/01/2005 - "The rates of ventilator-associated pneumonia (as defined by usual clinical and biological criteria plus positive culture of bronchoscopy directed catheter) acquisition between exposed and unexposed patients were compared by univariate analysis and then by multivariate analysis (conditional logistic regression and Cox's proportional-hazards model) to account for potential confounding factors. "
04/21/2010 - "Among mechanically ventilated adult ICU patients, early tracheotomy compared with late tracheotomy did not result in statistically significant improvement in incidence of ventilator-associated pneumonia. "
08/01/2007 - "In summary, the present study demonstrates that tracheotomy is independently associated with decreased risk for ventilator-associated pneumonia."
08/01/2007 - "The aim of the present study was to determine the relationship between tracheotomy and ventilator-associated pneumonia (VAP). "
06/01/2004 - "No data from randomized controlled trials actually support the thesis that tracheotomy reduces the incidence of ventilator-associated pneumonia. "
11/01/2014 - "In the slight sedation group, the incidences of ventilator-associated pneumonia (26% vs 53%) and tracheotomy (18% vs 48%) were significantly decreased compared with those in the usual group. "